MARKET

JAGX

JAGX

Jaguar Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.100
-0.030
-1.41%
After Hours: 2.110 +0.01 +0.48% 19:58 02/26 EST
OPEN
2.130
PREV CLOSE
2.130
HIGH
2.240
LOW
2.025
VOLUME
7.78M
TURNOVER
--
52 WEEK HIGH
4.470
52 WEEK LOW
0.1850
MARKET CAP
256.74M
P/E (TTM)
-1.1082
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
4 Cheap Penny Stocks To Watch Under $3 Before March 2021
Feb 24, 2021 (Penny Stocks via COMTEX) -- Are These Cheap Stocks On Your Watch List This Week? The markets are ablaze with upbeat sentiment, and penny stocks...
Penny Stocks · 4d ago
3 Biotech Penny Stocks to Watch as February Approaches
Feb 24, 2021 (Penny Stocks via COMTEX) -- Will These Biotech Penny Stocks Continue to Make Moves Next Month? With February right around the corner, we see...
Penny Stocks · 4d ago
Tuesday Sector Laggards: Biotechnology, Drugs
Feb 23, 2021 (MarketNewsVideo.com via COMTEX) -- In trading on Tuesday, biotechnology shares were relative laggards, down on the day by about 5.4%. Helping...
MarketNewsVideo.com · 5d ago
Jaguar Health launches website for Napo EU
Jaguar Health ([[JAGX]] -15.6%) announced that the company has launched the website for Napo EU, the anticipated subsidiary of Jaguar in Italy.The resources page of the site contains links to an
Seekingalpha · 5d ago
Jaguar Health Highlights Launch Of Website For Napo EU
Site contains links to information about post-COVID-19 ‘long-hauler' syndrome An article published yesterday in the San Francisco Chronicle references diarrhea as long-hauler symptom and the theory that the
Benzinga · 5d ago
Jaguar Health Launches Website for Napo EU
(NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has launched the website for Napo EU, the anticipated subsidiary of the Company in Italy. Click here to visit the website.
ACCESSWIRE · 5d ago
Jaguar Health Announces Commitment to Move Forward with Exclusive Relationship with the Planned Dragon SPAC, which is Pursuing Listing on AIM Italia and Plans to Target Napo EU
Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in EuropeSAN FRANSISCO, CA / ACCESSWIRE / February 19, 2021 / Jaguar Health...
ACCESSWIRE · 02/19 21:40
Jaguar Health In MoU With Dragon SPAC As Its Subsidiary Seeks Approval For Crofelemer In Europe
Benzinga · 02/18 18:11
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAGX. Analyze the recent business situations of Jaguar Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JAGX stock price target is 3.750 with a high estimate of 3.750 and a low estimate of 3.750.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 2.38M
% Owned: 1.95%
Shares Outstanding: 122.26M
TypeInstitutionsShares
Increased
5
1.58M
New
15
-242.60K
Decreased
1
104.86K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Independent Director
James Bochnowski
President/Chief Executive Officer/Director
Lisa Conte
Executive Vice President/Secretary
Steven King
Senior Vice President - Finance/Chief Accounting Officer
Carol Lizak
Senior Vice President
Melissa Yeager
Chief Compliance Officer/General Counsel
Jonathan Wolin
Independent Director
Gregory Divis
Independent Director
John Micek
Independent Director
Jiahao Qiu
Independent Director
Jonathan Siegel
  • Dividends
  • Splits
  • Insider Activity
No Data
About JAGX
Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Webull offers kinds of Jaguar Health Inc stock information, including NASDAQ:JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.